03 Jul Diabetes Medication Reduced Weight and Improved Metabolic Parameters in Obese Patients
MedicalResearch.com Interview with:
Dr. F. Xavier Pi–Sunyer MD
Division of Endocrinology and Obesity Research Center
Columbia University, New York
Medical Research: What is the background for this study? What are the main findings?
Dr. Pi-Sunye: In a large randomized trial, the drug Liraglutide was compared to placebo in overweight and obese non-diabetic volunteers. Over 52 weeks, in combination with diet and increased physical activity, Liraglutide lowered body weight by 8.4 kg as compared to 2.8 kg in placebo. 63% vs 27% lost at least 5% of baseline weight, 33% vs 10% lost more than 10% of baseline weight.
Medical Research: What are the implications of this report?
Dr. Pi-Sunye: This medication adds to the armamentarium physicians will have in helping overweight and obese patients lose weight and maintain it off.
Medical Research: What is the take home message?
Dr. Pi-Sunye: Liraglutide can lower weight, improve cardiovascular risk factors and improve quality of life. It can also reduce the progression to type 2 diabetes from prediabetes.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Pi-Sunye: I think it would be an advance if an oral analogue to this medication could be developed.
Citation:
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
N Engl J Med 2015; 373:11-22
July 2, 2015 DOI: 10.1056/NEJMoa1411892
[wysija_form id=”3″]
Dr. F. Xavier Pi-Sunyer MD, & Division of Endocrinology and Obesity Research Center (2015). Diabetes Medication Reduced Weight and Improved Metabolic Parameters in Obese Patients
Last Updated on July 3, 2015 by Marie Benz MD FAAD